Response rates for first- and second-generation EGFR-TKIs as first-line treatments have been reported to be 60-80%, with PFS duration of 9-13 months [6-11]. Furthermore, in a retrospective analysis, the median PFS duration for EGFR-TKI treatment was reported to be 8.3 months (95% CI: 5.5-14.8 months) in 21 patients with EGFR-mutant, EGFR-TKI-naive LA-NSCLC who relapsed after the standard chemoradiation [12]. The efficacy of the retreatment in our study is comparable to or superior to that in these previous studies [6-12]. Here, EGFR is linked to non-small cell lung carcinoma.